Pharmacies and wholesalers claimed Takeda Pharmaceutical delayed generic competition from entering the market, forcing them to overpay for a gastrointestinal drug. Takeda said the trial had “evidentiary and legal errors,” and the company will appeal the verdict.
The FDA will provide faster regulatory review of generic drugs that are tested and manufactured in the U.S. using domestically sourced active pharmaceutical ingredients. This FDA pilot program is part of a broader Trump administration strategy to reshore pharmaceutical production.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.